Liver injury in HIV monoinfected patients: Should we turn a blind eye to it?

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 5, 2012, Pages 441-447

  Lemoine, Maud ^a   Ingiliz, Patrick ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Medical Center for Infectious Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INSULIN; LIVER ENZYME; MARAVIROC; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIPRANAVIR; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOIMMUNE LIVER DISEASE; AUTOPHAGY; BILE DUCT CARCINOMA; CANCER INCIDENCE; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INJURY SEVERITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER TUMOR; LIVER VEIN; LIVER VEIN THROMBOSIS; MYCOBACTERIUM TUBERCULOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; RISK FACTOR; SHORT SURVEY; TOXIC HEPATITIS; TUBERCULOSIS; VIRUS HEPATITIS; VIRUS LOAD; VIRUS STRAIN;

HIV INFECTIONS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS;

EID: 84868365602     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.06.002     Document Type: Short Survey

References (62)

1. Joshi D., O'Grady J., Dieterich D., Gazzard B., Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011, 377(9772):1198-1209.
2. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010, 50:1387-1396. The Antiretroviral Therapy Cohort Collaboration.
3. Weber R., Sabin C.A., Friis-Moller N., Reiss P., El-Sadr W.M., Kirk O., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166(15):1632-1641.
4. Lacombe K., Bottero J., Lemoine M., Boyd A., Girard P.M. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2010, 65(1):10-17.
5. Kovari H., Ledergerber B., Battegay M., Rauch A., Hirschel B., Foguena A.K., et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010, 50(4):502-511.
6. Sterling R.K., Chiu S., Snider K., Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C co-infections. Dig Dis Sci 2008, 53(5):1375-1382.
7. Crum-Cianflone N., Collins G., Medina S., Asher D., Campin R., Bavaro M., et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol 2009, 8(2):183-191.
8. DallaPiazza M., Amorosa V.K., Localio R., Kostman J.R., Lo Re V. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010, 10:116.
9. th conference on retroviruses and opportunistic infections 2006, Denver, CO, USA, [Abstract 842].
10. Blanco F., Barreiro P., Ryan P., Vispo E., Martin-Carbonero L., Tuma P., et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011, 18(1):11-16.
11. Zatonski W.A., Sulkowska U., Manczuk M., Rehm J., Boffetta P., Lowenfels A.B., et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010, 16(4):193-201.
12. Ewing J.A. Detecting alcoholism. The CAGE questionnaire. JAMA 1984, 252(14):1905-1907.
13. Bertholet N., Cheng D.M., Samet J.H., Quinn E., Saitz R. Alcohol consumption patterns in HIV-infected adults with alcohol problems. Drug Alcohol Depend 2010, 112(1-2):160-163.
14. Galvan F.H., Bing E.G., Fleishman J.A., London A.S., Caetano R., Burnam M.A., et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol 2002, 63(2):179-186.
15. Shuper P.A., Joharchi N., Irving H., Rehm J. Alcohol as a correlate of unprotected sexual behavior among people living with HIV/AIDS: review and meta-analysis. AIDS Behav 2009, 13(6):1021-1036.
16. Rosenthal E., Pialoux G., Bernard N., Pradier C., Rey D., Bentata M., et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 study). J Viral Hepat 2007, 14(3):183-188.
17. Salmon-Ceron D., Lewden C., Morlat P., Bevilacqua S., Jougla E., Bonnet F., et al. Liver disease as a major cause of death among HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005, 42(6):799-805.
18. Chaudhry A.A., Sulkowski M.S., Chander G., Moore R.D. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med 2009, 10(3):133-142.
19. Samet J.H., Horton N.J., Meli S., Freedberg K.A., Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 2004, 28(4):572-577.
20. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010, 52(3):1143-1155.
21. De Lazzari E., Leon A., Arnaiz J.A., Martinez E., Knobel H., Negredo E., et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008, 9(4):221-226.
22. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358(6):568-579.
23. Rockstroh J., Teppler H., Zhao J., Sklar P., Harvey C., Strohmaier K., et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus co-infection. HIV Med 2012, 13(2):127-131.
24. Molina J.M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378(9787):238-246.
25. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50(8):1844-1850.
26. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000.
27. Palacios R., Merchante N., Macias J., Gonzalez M., Castillo J., Ruiz J., et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006, 11(4):529-535.
28. Castaneda-Sceppa C., Bermudez O.I., Wanke C., Forrester J.E. Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2008, 15(12):878-887.
29. Grunfeld C., Rimland D., Gibert C.L., Powderly W.G., Sidney S., Shlipak M.G., et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007, 46(3):283-290.
30. Worm S.W., Friis-Moller N., Bruyand M., D'Arminio Monforte A., Rickenbach M., Reiss P., et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010, 24(3):427-435.
31. Hadigan C., Liebau J., Andersen R., Holalkere N.S., Sahani D.V. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007, 46(3):312-317.
32. Guaraldi G., Squillace N., Stentarelli C., Orlando G., D'Amico R., Ligabue G., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008, 47(2):250-257.
33. Lemoine M., Barbu V., Girard P.M., Kim M., Bastard J.P., Wendum D., et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006, 20(3):387-395.
34. Ingiliz P., Valantin M.A., Duvivier C., Medja F., Dominguez S., Charlotte F., et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009, 49(2):436-442.
35. Lemoine M., Serfaty L., Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 2012, 25(1):10-16.
36. Lemoine M., Capeau J., Serfaty L. PPAR and liver injury in HIV-infected patients. PPAR Res 2009, 2009:906167.
37. Caron-Debarle M., Lagathu C., Boccara F., Vigouroux C., Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010, 16(5):218-229.
38. Li J.C., Au K.Y., Fang J.W., Yim H.C., Chow K.H., Ho P.L., et al. HIV-1 trans-activator protein dysregulates IFN-gamma signaling and contributes to the suppression of autophagy induction. AIDS 2011, 25(1):15-25.
39. Parker R.A., Flint O.P., Mulvey R., Elosua C., Wang F., Fenderson W., et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005, 67(6):1909-1919.
40. Liu H.Y., Han J., Cao S.Y., Hong T., Zhuo D., Shi J., et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem 2009, 284(45):31484-31492.
41. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53(2):372-384.
42. Buckley J.A., Hutchins G.M. Association of hepatic veno-occlusive disease with the acquired immunodeficiency syndrome. Mod Pathol 1995, 8(4):398-401.
43. Kovari H., Ledergerber B., Peter U., Flepp M., Jost J., Schmid P., et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009, 49(4):626-635.
44. Mallet V., Blanchard P., Verkarre V., Vallet-Pichard A., Fontaine H., Lascoux-Combe C., et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007, 21(2):187-192.
45. Mallet V.O., Varthaman A., Lasne D., Viard J.P., Gouya H., Borgel D., et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009, 23(12):1511-1518.
46. Puius Y.A., Dove L.M., Brust D.G., Shah D.P., Lefkowitch J.H. Three cases of autoimmune hepatitis in HIV-infected patients. J Clin Gastroenterol 2008, 42(4):425-429.
47. Fainboim H., Schroder T., Baiges D., Paz S., Estepo C.R., Tauterys M., et al. Seven cases of autoimmune hepatitis in HIV-infected patients: Characteristics and possible role of HIV. Hepatology 2010, 52(Suppl. 4):1119A.
48. Mason A.L., Xu L., Guo L., Munoz S., Jaspan J.B., Bryer-Ash M., et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998, 351(9116):1620-1624.
49. Vallet-Pichard A., Fontaine H., Mallet V., Pol S. VIRAL hepatitis in solid organ transplantation other than liver. J Hepatol 2011, 55(2):474-482.
50. Maylin S., Stephan R., Molina J.M., Peraldi M.N., Scieux C., Nicand E., et al. Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. J Clin Virol 2012, 53(4):346-349.
51. Keane F., Gompels M., Bendall R., Drayton R., Jennings L., Black J., et al. Virus co-infection in patients with HIV infection. HIV Med 2012, 13(1):83-88.
52. Colson P., Dhiver C., Poizot-Martin I., Tamalet C., Gerolami R. Acute and chronic hepatitis E in patients infected with human immunodeficiency virus. J Viral Hepat 2011, 18(3):227-228.
53. Dalton H.R., Bendall R.P., Keane F.E., Tedder R.S., Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009, 361(10):1025-1027.
54. Kaba M., Richet H., Ravaux I., Moreau J., Poizot-Martin I., Motte A., et al. Virus infection in patients infected with the human immunodeficiency virus. J Med Virol 2011, 83(10):1704-1716.
55. Salmon-Ceron D., Rosenthal E., Lewden C., Bouteloup V., May T., Burty C., et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009, 50(4):736-745.
56. Puoti M., Bruno R., Soriano V., Donato F., Gaeta G.B., Quinzan G.P., et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18(17):2285-2293.
57. Brau N., Fox R.K., Xiao P., Marks K., Naqvi Z., Taylor L.E., et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007, 47(4):527-537.
58. Clifford G.M., Rickenbach M., Polesel J., Dal Maso L., Steffen I., Ledergerber B., et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22(16):2135-2141.
59. Salmon D., Bani-Sadr F., Loko M.A., Stitou H., Gervais A., Durant J., et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol 2012, 56(4):862-868.
60. Bourcier V., Winnock M., Ait Ahmed M., Sogni P., Pambrun E., Poizot-Martin I., et al. Primary liver cancer is more aggressive in HIV-HCV co-infection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012, 36(3):214-221.
61. Shaib Y.H., El-Serag H.B., Davila J.A., Morgan R., McGlynn K.A. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128(3):620-626.
62. Monforte A., Abrams D., Pradier C., Weber R., Reiss P., Bonnet F., et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008, 22(16):2143-2153.